The study, published online in the journal Cancer, included 59,806 women ages 50 to 79. Researchers gathered health and lifestyle data at the start of the study, and the women reported their health in yearly questionnaires over an average 12 years of follow-up. The women brought in their medicine bottles for the researchers to examine and record.
There were 548 incidents of melanoma during the period. After controlling for sun exposure, sunscreen use, a history of skin cancer and many other factors, the researchers found that women who reported using aspirin had an average 21 percent lower risk of melanoma compared with nonusers, and the longer they used aspirin, the lower their risk.
The reasons for the effect are unclear, but the authors suggest that aspirin’s known effect in promoting cell death and activating tumor suppressor genes may be factors.
The senior author, Dr. Jean Y. Tang, an assistant professor of dermatology at Stanford, pointed out that the study was observational and not a clinical trial, and correlation does not equal causation. “It’s an important finding for high-risk women to discuss with their doctors,” she said, “but it’s way too early to recommend that everyone go take aspirin to prevent melanoma.”
Comment: It is discouraging that the Cancer (Journal) article is not free open access, considering that federal funds were probably used for the study. The question is whether the relative risk reduction outweighs aspirin's known side-effects.
Reference:
Aspirin
is associated with lower melanoma risk among postmenopausal Caucasian women:
The Women's Health Initiative. Gamba CA, et. al. Cancer. 2013 Mar 11. doi:
10.1002/cncr.27817.
Source: Stanford University
School of Medicine and Cancer Institute, Stanford, California.
One needs to understand the difference between Relative Risk and Absolute Risk to judge the value of this finding. See: RR vs. AR article.